Tag: sale

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

Establishes Top 25 National Homebuilder with Strong Foundation for Growth

In accordance with section 30 of the Capital Markets Act, Pandora A/S hereby announces that
BlackRock, Inc. has notified the company that it now holds 7,485,780 shares, corresponding to 9.47% of the total voting rights and share capital (previously 9.51%). Additionally, BlackRock, Inc. controls voting rights attached to financial instruments amounting to 0.50% (previously 0.49%). In total, BlackRock, Inc. control 9.98% of the company’s voting rights (previously 10.01%).

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara.

WEST DES MOINES, Iowa, June 24, 2025 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) today announced it has agreed to sell $600 million aggregate principal amount of 6.875% fixed-rate reset junior subordinated debentures due June 28, 2055. The offering is expected to close on June 27, 2025, subject to satisfaction of customary closing conditions.